Cargando…

Outcomes of Primary Furlow Double-Opposing Z-plasty for the Treatment of Symptomatic Submucous Cleft Palate

BACKGROUND: Submucous cleft palate (SMCP) requires surgical repair if symptomatic. The Furlow double-opposing Z-plasty is the preferred method in Helsinki cleft center. AIMS: To assess the efficacy and complications of Furlow Z-plasty in the treatment of symptomatic SMCP. METHODS: This retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Pitkänen, Veera, Szwedyc, Anika, Alaluusua, Suvi, Geneid, Ahmed, Vuola, Pia, Saarikko, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521778/
https://www.ncbi.nlm.nih.gov/pubmed/37221637
http://dx.doi.org/10.1097/SCS.0000000000009385
_version_ 1785110210175565824
author Pitkänen, Veera
Szwedyc, Anika
Alaluusua, Suvi
Geneid, Ahmed
Vuola, Pia
Saarikko, Anne
author_facet Pitkänen, Veera
Szwedyc, Anika
Alaluusua, Suvi
Geneid, Ahmed
Vuola, Pia
Saarikko, Anne
author_sort Pitkänen, Veera
collection PubMed
description BACKGROUND: Submucous cleft palate (SMCP) requires surgical repair if symptomatic. The Furlow double-opposing Z-plasty is the preferred method in Helsinki cleft center. AIMS: To assess the efficacy and complications of Furlow Z-plasty in the treatment of symptomatic SMCP. METHODS: This retrospective study reviewed documentation of 40 consecutive patients with symptomatic SMCP who underwent primary Furlow Z-plasty by 2 high-volume cleft surgeons at a single center between 2008 and 2017. Patients underwent perceptual and instrumental evaluation of velopharyngeal function (VPF) by speech pathologists preoperatively and postoperatively. RESULTS: The median age at Furlow Z-plasty was 4.8 years (SD 2.6, range 3.1–13.6). The overall success rate, including postoperative competent or borderline competent VPF, was 83%, and 10% required secondary surgery for residual velopharyngeal insufficiency. The success rate was 85% in nonsyndromic, and 67% in syndromic patients with no significant difference (P=0.279). Complications arose in only 2 (5%) patients. No children were found to have obstructive sleep apnea postoperatively. CONCLUSION: Furlow primary Z-plasty is a safe and effective operation for symptomatic SMCP with a success rate of 83% with only 5% rate of complications.
format Online
Article
Text
id pubmed-10521778
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-105217782023-09-27 Outcomes of Primary Furlow Double-Opposing Z-plasty for the Treatment of Symptomatic Submucous Cleft Palate Pitkänen, Veera Szwedyc, Anika Alaluusua, Suvi Geneid, Ahmed Vuola, Pia Saarikko, Anne J Craniofac Surg Clinical Studies BACKGROUND: Submucous cleft palate (SMCP) requires surgical repair if symptomatic. The Furlow double-opposing Z-plasty is the preferred method in Helsinki cleft center. AIMS: To assess the efficacy and complications of Furlow Z-plasty in the treatment of symptomatic SMCP. METHODS: This retrospective study reviewed documentation of 40 consecutive patients with symptomatic SMCP who underwent primary Furlow Z-plasty by 2 high-volume cleft surgeons at a single center between 2008 and 2017. Patients underwent perceptual and instrumental evaluation of velopharyngeal function (VPF) by speech pathologists preoperatively and postoperatively. RESULTS: The median age at Furlow Z-plasty was 4.8 years (SD 2.6, range 3.1–13.6). The overall success rate, including postoperative competent or borderline competent VPF, was 83%, and 10% required secondary surgery for residual velopharyngeal insufficiency. The success rate was 85% in nonsyndromic, and 67% in syndromic patients with no significant difference (P=0.279). Complications arose in only 2 (5%) patients. No children were found to have obstructive sleep apnea postoperatively. CONCLUSION: Furlow primary Z-plasty is a safe and effective operation for symptomatic SMCP with a success rate of 83% with only 5% rate of complications. Lippincott Williams & Wilkins 2023-10 2023-05-24 /pmc/articles/PMC10521778/ /pubmed/37221637 http://dx.doi.org/10.1097/SCS.0000000000009385 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of Mutaz B. Habal, MD. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/) (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Clinical Studies
Pitkänen, Veera
Szwedyc, Anika
Alaluusua, Suvi
Geneid, Ahmed
Vuola, Pia
Saarikko, Anne
Outcomes of Primary Furlow Double-Opposing Z-plasty for the Treatment of Symptomatic Submucous Cleft Palate
title Outcomes of Primary Furlow Double-Opposing Z-plasty for the Treatment of Symptomatic Submucous Cleft Palate
title_full Outcomes of Primary Furlow Double-Opposing Z-plasty for the Treatment of Symptomatic Submucous Cleft Palate
title_fullStr Outcomes of Primary Furlow Double-Opposing Z-plasty for the Treatment of Symptomatic Submucous Cleft Palate
title_full_unstemmed Outcomes of Primary Furlow Double-Opposing Z-plasty for the Treatment of Symptomatic Submucous Cleft Palate
title_short Outcomes of Primary Furlow Double-Opposing Z-plasty for the Treatment of Symptomatic Submucous Cleft Palate
title_sort outcomes of primary furlow double-opposing z-plasty for the treatment of symptomatic submucous cleft palate
topic Clinical Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521778/
https://www.ncbi.nlm.nih.gov/pubmed/37221637
http://dx.doi.org/10.1097/SCS.0000000000009385
work_keys_str_mv AT pitkanenveera outcomesofprimaryfurlowdoubleopposingzplastyforthetreatmentofsymptomaticsubmucouscleftpalate
AT szwedycanika outcomesofprimaryfurlowdoubleopposingzplastyforthetreatmentofsymptomaticsubmucouscleftpalate
AT alaluusuasuvi outcomesofprimaryfurlowdoubleopposingzplastyforthetreatmentofsymptomaticsubmucouscleftpalate
AT geneidahmed outcomesofprimaryfurlowdoubleopposingzplastyforthetreatmentofsymptomaticsubmucouscleftpalate
AT vuolapia outcomesofprimaryfurlowdoubleopposingzplastyforthetreatmentofsymptomaticsubmucouscleftpalate
AT saarikkoanne outcomesofprimaryfurlowdoubleopposingzplastyforthetreatmentofsymptomaticsubmucouscleftpalate